Lv32
400 积分 2024-09-18 加入
High-Risk MCL: Recognition and Treatment
3小时前
待确认
Frontline Treatment of Mantle Cell Lymphoma
7小时前
已完结
New promises and challenges in the treatment of advanced non-small-cell lung cancer
16天前
已完结
BTK inhibitor selection for chronic lymphocytic leukemia: which drug for which patient?
17天前
已完结
Pemigatinib for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
1个月前
已关闭
A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis
1个月前
已关闭
New bispecific antibodies in diffuse large B-cell lymphoma
1个月前
已完结
A Systematic Review of the Epidemiology and Economic Burden of Mantle Cell Lymphoma (MCL)
1个月前
已关闭
Towards a chemo‐free approach for follicular lymphoma
1个月前
已完结
Treatment of Relapsed/Refractory MCL
1个月前
已完结
皖公网安备34019202002308
